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Abstract 
Background: To identify potential prognostic factors among patients with favorable intermediate risk prostate can‑
cer with a biopsy Gleason score 6.
Methods: From 2003 to 2019, favorable intermediate risk patients who underwent radical prostatectomy were 
included in this study. All patients were evaluated preoperatively with MRI. Using PI‑RADS scores, patients were 
divided into two groups, and clinic‑pathological outcomes were compared. The impact of preoperative factors on 
significant pathologic Gleason score upgrading (≥ 4 + 3) and biochemical recurrence were assessed via multivariate 
analysis. Subgroup analysis was performed in patients with PI‑RADS ≤ 2.
Results: Among the 239 patients, 116 (48.5%) were MRI‑negative (PI‑RADS ≤ 3) and 123 (51.5%) were MRI‑positive 
(PI‑RADS > 3). Six patients in the MRI‑negative group (5.2%) were characterized as requiring significant pathologic 
Gleason score upgrading compared with 34 patients (27.6%) in the MRI‑positive group (p < 0.001). PI‑RADS score was 
shown to be a significant predictor of significant pathologic Gleason score upgrading (OR = 6.246, p < 0.001) and bio‑
chemical recurrence (HR = 2.595, p = 0.043). 10‑years biochemical recurrence‑free survival was estimated to be 84.4% 
and 72.6% in the MRI‑negative and MRI‑positive groups (p = 0.035). In the 79 patients with PI‑RADS ≤ 2, tumor length 
in biopsy cores was identified as a significant predictor of pathologic Gleason score (OR = 11.336, p = 0.014).
Conclusions: Among the patients with favorable intermediate risk prostate cancer with a biopsy Gleason score 6, 
preoperative MRI was capable of predicting significant pathologic Gleason score upgrading and biochemical recur‑
rence. Especially, the patients with PI‑RADS ≤ 2 and low biopsy tumor length could be a potential candidate to active 
surveillance.
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Background
Clinically localized prostate cancer can be managed with 
active surveillance (AS) [1]. Importantly, AS has emerged 
as a preferred initial management strategy for patients 
with low-risk (LR) PCa as it helps decrease the overtreat-
ment of clinically indolent disease [2]. The safety and 
utility of AS in patients with LR PCa was confirmed and 
its use has rapidly increased worldwide. However, the 
utility of AS in patients with intermediate risk (IR) PCa 
remains unclear [3].
In the United States SEER (Surveillance, Epidemiology 
and End Results)-Medicare program, expectant manage-
ment of LR PCa cases increased from 22 to 43% between 
2004 and 2011; 15% to 18% of IR PCa cases were man-
aged conservatively [4]. According to the National Com-
prehensive Cancer Network (NCCN) stratification, those 
classified within the favorable intermediate risk (FIR) 
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group had better prognoses compared with those within 
the unfavorable intermediate risk (UFIR) group [5]; other 
studies revealed similar oncological results compared to 
LR PCa [6, 7]. Data from one long-term study revealed 
that a similar percentage of those in the IR group with a 
biopsy Gleason score of 6 and PSA between 10–20  ng/
ml experienced 15-year metastatic-free survival com-
pared to those with LR PCa (94% for both groups) [3]. 
Therefore, here we evaluated the potential utility of AS in 
individuals within the IR group, specifically those charac-
terized as FIR.
Biochemical recurrence rates (BCR) following defini-
tive primary treatment for IR PCa vary dramatically, 
with 5-year rates ranging from 2 to 70% [8–11]. Of note, 
current criteria for AS have a misclassification rate of 
between 15–30% [12–15]. Another study revealed that 
individuals with a bGS of 6 and a PSA between 10 and 
20  ng/ml are at higher risk of pathologic Gleason score 
upgrading (PGU) and upstaging, making them poor 
candidates for AS [2]. A rate of 50% PGU has been 
reported in a variety of studies [16–18], suggesting that 
not all patients with bGS of 6 may be characterized 
appropriately.
Therefore, in this study, we characterized the outcomes 
of patients with FIR PCa who have a bGS of 6 and PSA 
between 10 and 20 ng/ml. Prognosis using MRI according 
to stratification was analyzed, and potential prognostica-
tors were investigated among patients (and subgroups) 
with FIR PCa and clear MRI results.
Methods
All data analysis was carried out in accordance with 
applicable laws and regulations described in the Decla-
ration of Helsinki and approved by institutional review 
board approval (Seoul National University Bundang 
Hospital (B-2004–608-104), we reviewed the records of 
patients who underwent radical prostatectomy (RP) in 
a single tertiary hospital between November 2003 and 
April 2019. Among them, patients with FIR PCa, pre-
operative bGS of 6, PSA between 10 and 20  ng/ml and 
a percent of positive biopsy cores < 50% were finally 
enrolled. All patients received ≥ 12 core transrectal pros-
tate biopsy (MR fusion) and preoperative prostate MRI.
Prostate MRI exams were conducted 2–6  weeks after 
transrectal ultrasound–guided biopsy and before surgery. 
Prostate MRI up to 2006 was acquired in a biparametric 
manner including T2-weighted image (T2WI) and diffu-
sion-weighted image (DWI). Since 2007, multiparamet-
ric prostate MRI, including dynamic contrast-enhanced 
(DCE) image, have been obtained. As PI-RADS was 
released and revised during this period, and to minimize 
the bias that may occur due to accumulated MRI read-
ing experience over time, an experienced uroradiologist 
blinded from relevant information reviewed the preop-
erative MRI of the included patients for this retrospective 
study. Final scores for each patient were assigned accord-
ing to PI-RADS (version 2) standards on a 5-point scale 
[19, 20]. The probability of clinically significant cancer 
was defined as follows: 1 (very low), 2 (low), 3 (intermedi-
ate), 4 (high), and 5 (very high).
Enrolled patients were stratified into two group accord-
ing to preoperative MRI findings—the MRI-negative 
group (PI-RADS < 4) and the MRI-positive group (PI-
RADS ≥ 4). Baseline characteristics [ie, age, body mass 
index (BMI), prostate volume, PSA, percent of positive 
biopsy core (%), total tumor length in cores, percentage 
of total tumor of all cores] between the two groups were 
compared using the student-t and chi-square tests.
RP specimens were assessed as previously reported 
[21]. Pathological parameters [ie, pGS, PGU, extracapsu-
lar extension (ECE), seminal vesicle invasion (SVI), posi-
tive surgical margin (PSM), pathologic tumor volume] 
were compared. We defined significant PGU (SPGU) as 
pathologic Gleason score ≥ 4 + 3 from bGS 6. All biopsy 
and RP pathology was newly reviewed by one uro-pathol-
ogist. A multivariate analysis was performed to predict 
SPGU using preoperative parameters and the PI-RADS 
grouping. Median follow-up duration was 58  months. 
BCR was defined as postoperative PSA ≥ 0.2  ng/mL 
taken twice at least 6 weeks apart [22]. Multivariate Cox 
proportional hazard model was also performed to predict 
BCR using preoperative parameters. A subgroup analy-
sis was conducted in patients whose preoperative MRI 
showed no significant lesions and identified other preop-
erative parameters that could be predictors of PGU.
Results
In all, 239 patients with bGS of 6 and PSA between 10 
and 20 ng/ml were enrolled in this study. Among them, 
116 (48.5%) were placed into the MRI-negative group and 
123 (51.5%) into the MRI-positive group. As shown in 
Table 1, those in the MRI-positive group had: i) a higher 
percentage of positive cores (28.51 vs. 20.42%, p = 0.003), 
ii) longer tumor lengths (0.51 vs. 0.32, mm, p < 0.001) and 
iii) percentage of total tumors of cores (32.02 vs. 20.76, 
%, p < 0.001). In the MRI-positive group, 64 (52.0%) and 
59 (48.0%) of patients had PI-RADS scores of 4 and 5, 
respectively.
Pathological outcomes are presented in Table  2. A 
total of 199 (83.3%) and 40 (16.7%) of patients, respec-
tively demonstrated PGU and SPGU. The percentage of 
patients demonstrated PGU was significantly higher in 
the MRI-positive group (96.7%) compared with the MRI-
negative group (69.0%) (p < 0.001); similar results were 
noted for SPGU (≥ 4 + 3) (27.6% vs 5.2% in the MRI-pos-
itive and MRI-negative group, respectively) (p < 0.001). 
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Other parameters (ie, ECE, PSM, pathologic tumor vol-
ume) were also higher in the MRI-positive group com-
pared with the MRI-negative group (all p < 0.001).
A multivariate analysis revealed that SPGU, PI-RADS 
(OR 6.246, 95% CI 2.400–16.255, p < 0.001) and per-
centage of total tumors of core (OR 1.049, 95% CI 
Table 1 Baseline characteristics who intermediate risk prostate cancer patients with biopsy Gleason score 6 and comparisons 
according to multi‑parametric MRI finding
BMI; body mass index, PSA; prostate specific antigen, DM; diabetes mellitus, HTN; hypertension, PIRADS; Prostate Imaging Reporting and Data System,
Total MR‑negative MR‑positive p value
Number 239 116 (48.5) 123 (51.5)
Mean Age (years, ± SD) 65.79 ± 6.60 65.37 ± 7.15 66.19 ± 6.03 0.340
Mean BMI (± SD) 24.49 ± 2.64 24.41 ± 2.75 24.56 ± 2.55 0.678
Prostate volume 42.22 ± 18.43 45.27 ± 19.76 39.35 ± 16.65 0.013
PSA 13.51 ± 2.82 13.46 ± 2.86 13.56 ± 2.79 0.801
Median PSA 12.64 12.32 13.00
Mean PSA density 0.37 ± 0.16 0.36 ± 0.17 0.39 ± 0.15 0.085
DM (%) 25 (10.5) 11 (9.5) 14 (11.4) 0.395
HTN (%) 113 (47.3) 54 (46.6) 59 (48.0) 0.464
Number of biopsy (%) 0.262
12 164 (68.6) 80 (69.0) 84 (68.3)
 ≥ 13 75 (31.4) 36 (31.0) 39 (31.7)
Mean percentage of positive core (%, ± SD) 24.44 ± 19.97 20.42 ± 17.09 28.51 ± 21.85 0.003
Mean tumor length (mm, ± SD) 0.41 ± 0.34 0.32 ± 0.26 0.51 ± 0.39  < 0.001
Mean percentage of total tumor of core (%, ± SD) 26.47 ± 22.50 20.76 ± 18.05 32.02 ± 24.96  < 0.001
PIRADS score (%)
2 79 (33.1) 79
3 37 (15.5) 37
4 64 (26.8) 64
5 59 (24.7) 59
Table 2 Pathological outcomes after radical prostatectomy among favorable intermediate risk prostate cancer patients with biopsy 
Gleason score 6 and comparison according to multi‑parametric MRI finding
Total MR‑negative MR‑positive p‑value
Number 239 116 (48.5) 123 (51.5)
Pathologic Gleason score (%)  < 0.001
6 40 (16.7) 36 (31.0) 4 (3.3)
3 + 4 159 (66.5) 74 (63.8) 85 (69.1)
4 + 3 38 (15.9) 5 (4.3) 33 (26.8)
8 2 (0.8) 1 (0.9) 1 (0.8)
Pathologic Gleason score upgrading (%) 199 (83.3) 80 (69.0) 119 (96.7)  < 0.001
Pathologic significant Gleason score upgrading (≥ 4 + 3) 
(%)
40 (16.7) 6 (5.2) 34 (27.6)  < 0.001
Extracapsular invasion (%) 50 (20.9) 10 (8.6) 40 (32.5)  < 0.001
Seminal vesicle invasion (%) 9 (3.8) 4 (3.4) 5 (4.1) 0.813
Bladder neck invasion (%) 6 (2.5) 1 (0.9) 5 (4.1) 0.116
Lymph node invasion 0
Positive surgical margin (%) 53 (22.2) 13 (11.2) 40 (32.5)  < 0.001
Mean pathologic tumor volume (%, ± SD) 0.13 ± 0.14 0.07 ± 0.97 0.18 ± 0.16  < 0.001
Mean pathologic tumor volume (cc, ± SD) 5.16 ± 6.39 3.09 ± 3.96 7.11 ± 7.53  < 0.001
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1.014–1.086, p < 0.006) were significant predictors of 
SPGU (Table 3).
During a median follow-up of 58  months, 31 patients 
experienced BCR. 10-year BCR-free survival was 
achieved by 83.2% and 54.8% of those in the MRI-nega-
tive and MRI-positive groups, respectively (log rant test 
p = 0.027, Fig. 1). A mutivariate Cox proportional hazard 
model revealed that prostate volume (HR = 0.956, 95% CI 
0.923–0.991, p = 0.013) and PI-RADS score (HR = 2.595, 
95% CI 1.949–7.098, p = 0.043) were significant predic-
tors of BCR (Table 4).
A subgroup analysis of the 79 patients with bGS of 6, 
PSA between 10-20  ng/ml and PI-RADS < 3, revealed 
that 48 (60.8%) and 10 (12.7%) required PGU and SPGU, 
respectively. Among this subgroup, BCR occurred in only 
4 patients (5.1%). 10-year BCR-free survival was 84.4%. 
Multivariate analysis was used to predict PGU in this 
group and results are presented in Table 5. Tumor length 
as assessed from biopsy cores was a significant predictor 
of PGU (OR: 11.336, p = 0.014).
Discussion
In the current study, we investigated potential prognos-
ticators of individuals with FIR PCa, a bGS of 6 and a 
PSA between 10 and 20 ng/ml. Among the 239 patients 
included: i) 10-year BCR-free survival was estimated to 
be 70.9%, ii) PGU and SPGU from bGS 6 were deter-
mined to be 83.3% and 16.7%, respectively, iii) and preop-
erative MRI findings were significantly predictors of PGU 
and SPGU. These results could help inform the selection 
of FIR patients who would be most appropriate for AS.
The possibility of using AS for patients in the IR risk 
group has been previously raised. Accumulating evidence 
suggests that FIR PCa may be similar biologically to LR 
PCa. For instance, a previous study revealed that there 
was no significant difference in BCR between those with 
FIR and LR PCa [5]. Additionally, this study reported 
5-year progression-free survival (PFS) rates of 93% and 
87% in LR and FIR risk groups, respectively (p = 0.054). 
These results are similar to what was observed in this 
study, namely a 10-year BCR-free survival rate of 70.9% 
in the FIR group.
Reports suggest that less aggressive IR cancer could 
be a potential candidate for AS. In particular, patients 
with Grade Group 1 (bGS 6) IR have been shown to 
have a low risk of progression to metastasis [23–26]. 
One large surveillance study (Sunnybrook in Toronto) 
reported data from a cohort of individuals receiv-
ing conservative treatment for IR PCa. Although the 
Table 3 Univariate and multivariate logistic regression analysis to predict pathologic significant Gleason score upgrading (≥ 4 + 3)
Univariate analysis Multivariate analysis
OR 95%CI p‑value OR 95%CI p‑value
Age 1.000 0.950–1.053 0.998
Bdoy mass index 1.092 0.958–1.245 0.186
DM 0.937 0.303–2.892 0.909
HTN 1.273 0.645–2.515 0.486
Prostate volume 0.981 0.960–1.003 0.087
PSA 0.936 0.824–1.063 0.310
PSA density 2.755 0.352–21.536 0.334
PIRADS (< 3 vs. ≥ 3) 6.940 2.788–17.275  < 0.001 6.246 2.400–16.255  < 0.001
Number of biopsy (12 vs. ≥ 13) 0.319 0.093–1.099 0.070
Mean percentage of positive core 1.007 0.990–1.025 0.431
Mean tumor length 3.667 1.493–9.005 0.005 0.133 0.014–1.285 0.081
Mean percentage of total tumor of core 1.027 1.012–1.041  < 0.001 1.049 1.014–1.086 0.006
Fig. 1 Kaplan‑meier analysis of biochemical recurrence free survival 
according to MRI negative and positive
Page 5 of 7Oh et al. BMC Urol           (2021) 21:52  
15-year PCa metastatsis rate was 3.7 times higher in the 
IR risk group compared with the LR group, the pres-
ence of Gleason 7 cancer at initial diagnosis accounted 
for almost all of this increase in risk [3]. Patients with 
a bGS of 6 and PSA between 10 and 20  ng/ml had an 
estimated 15-year metastasis-free survival rate of 94%, 
a rate very similar to patients with LR PCa. This group 
highlighted that a PSA above 10 did not confer a sig-
nificantly increased risk of metastasis in those without 
a cancer with a Gleason score of 4 [27]. Loeb et al. [28] 
revealed the patients with a bGS of 6 (Grade Group 1), 
PSA between 10 and 15 mg/ml and a PSA density less 
than 0.15  ng/ml did not significantly differ in adverse 
pathology findings when compared to those with LR 
PCa. As a result, the authors concluded that patients 
with bGS 6 IR PCa could be candidates for AS.
It should be noted, however, that other studies with 
contradictory findings have also been published. Aghaz-
adeh et  al. [5] conducted a large study (3,686 patients) 
which compared prognoses between FIR and LR PCa. 
The rate of adverse pathological findings in those with 
FIR was significantly higher when compared with those 
with lower risk PCa and significantly lower when com-
pared with those with unfavorable intermediate risk PCa 
(27.4% vs 14.8% and 48.5%, respectively, each p < 0.001). 
In an Asian population study, the FIR group had signifi-
cantly lower 5-year BCR-free survival when compared 
with the LR group (87.5 vs 93.5%; P = 0.002) [29]. These 
Table 4 Univariate and multivariate Cox proportional hazards analysis to predict biochemical recurrence after radical prostatectomy
Univariate analysis Multivariate analysis
HR 95%CI p‑value HR 95%CI p‑value
Age 0.967 0.911–1.027 0.274
Bdoy mass index 1.116 0.962–1.295 0.148
DM 0.314 0.042–2.327 0.257
HTN 1.854 0.793–4.335 0.154
Prostate volume 0.953 0.921–0.986 0.005 0.956 0.923–0.991 0.013
PSA 1.043 0.907–1.199 0.555
PSA density 14.810 2.307–95.077 0.004
PIRADS (< 3 vs. ≥ 3) 3.002 1.024–8.800 0.035 2.595 1.949–7.098 0.043
Number of biopsy (12 vs. ≥ 13) 1.162 0.422–3.202 0.772
Mean percentage of positive core 1.022 0.005–1.040 0.012 1.345 0.632–2.863 0.442
Mean tumor length 2.114 0.786–5.681 0.138
Mean percentage of total tumor of core 1.012 0.997–1.027 0.117
Table 5 Univariate and multivariate logistic regression analysis to predict pathologic Gleason score upgrading among PIRADS ≤ 2 
patients
Univariate analysis Multivariate analysis
OR 95%CI p‑value OR 95%CI p‑value
Age 1.021 0.958–1.088 0.523
Bdoy mass index 1.100 0.925–1.307 0.280
DM 0.804 0.198–3.261 0.760
HTN 0.981 0.394–2.440 0.967
Prostate volume 0.984 0.962–1.007 0.173
PSA 0.991 0.844–1.164 0.915
PSA density 1.811 0.688–4.764 0.329
Number of biopsy (12 vs. ≥ 13) 0.615 0.196–1.933 0.406
Mean percentage of positive core 3.400 1.010–11.451 0.048 0.962 0.905–1.022 0.206
Mean tumor length 6.500 2.114–19.987 0.001 11.336 1.630–78.845 0.014
Mean percentage of total tumor of core 3.274 1.210–8.861 0.020 1.042 0.976–1.112 0.220
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results could be caused by a discrepancy between bGS 
and pathological Gleason score. Yang et al. reported that 
25.5% of patients with bGS 6 FIR PCa and PSA between 
10 and 20 ng/ml required PGU and pathological upstag-
ing [2]. Similarly, a report involving 359 men with bGS 6 
and PSA between 10 and 20  ng/ml who underwent RP, 
revealed that 40.4% patients required PGU; among this 
group, 5% were upgraded into GS ≥ 8 [30]. Here, 83.3% 
of patients required PGU after RP, 16.7% had pathologic 
GS above 4 + 3. These results suggest that a proportion of 
patients with Gleason score 6 at preoperative biopsy may 
always require PGU.
Advances in software and hardware technology has led 
to the development of multi-parametric MRI for use in 
the detection of prostate cancer. Validation of this and 
other MRI-based tools have been summarized in guide-
lines published by the European Society of Urogenital 
Radiology (ESUR) along with a scoring system for PCa 
known as PI-RADS. Seo et al. revealed that PI-RADS can 
serve as a predictor of GS upgrading, with an estimated 
accuracy of 0.672–0.685 [1]. Another study of 126 can-
cer foci demonstrated that: i) PIRAD scores were 90% 
accurate at predicting Gleason score agreement between 
biopsy and pathologic GS (OR: 2.64, p < 0.001) and ii) 
MRI findings were capable of predicting PGU. Here, it 
was revealed that PI-RADS scores were a significant pre-
dictor of PGU (OR: 7.407, p < 0.001, data not shown) and 
SPGU (OR: 6.246, p < 0.001). Therefore, patients with 
FIR PCa, a bGS of 6 and a PI-RADS score ≤ 3 may be 
good candidates for AS. Among them, estimated 10-year 
BCR-free survival for patients with PCa and a PI-RADS 
score ≤ 2 was 84.4%, as good or better than the results 
reported from other studies of patients with LR PCa (66% 
to 88%) [31, 32]. Therefore, patients with FIR PCa with 
preoperative MRI (PI-RADS score ≤ 2) appear to be the 
ideal candidate for AS; furthermore, AS was seven safer 
in a subset of these patients with smaller biopsy tumor 
lengths.
This study does have several limitations that should 
be mentioned, primarily, the limited number of subjects 
and retrospective nature. Additionally, the PI-RADS 
score was assigned on biparametric MRI in patients 
included in earlier period. However, the diagnostic per-
formance of the PI-RADS score of biparametric MRI is 
not reported to be inferior to that of multiparametric 
MRI [33]. Another limitation is the relatively high rate of 
PGU. The single pathologist who has a specialty for uro-
oncology reviewed all of the specimens included in this 
study through International Society of Urological Pathol-
ogy (ISUP) recommendation of modified Gleason score 
which announced in 2005 after handling by very thin sec-
tioned. Regardless the extent of tumor, any Gleason pat-
tern 4 was found in any section at radical prostatectomy 
specimen with 99% Gleason pattern 3, therefore Glea-
son score was 3 + 4. It was reason for high rate of PGU. 
In our results, 159 patients (79.9%) were pathologically 
upgraded to Gleason score 3 + 4 and only 38 patients 
(15.9%) to Gleason score 4 + 3 among 203 patients had 
experienced PGU after RP. The pathologic profiles of our 
participants appear to be relatively more aggressive (ie, 
higher PSA level, higher rate of high-grade disease) than 
those reported in western series. It is important to note 
that the rate of PSA screening in Asia is still not as high 
as in Western countries [34].
Conclusions
Among the patients with FIR PCa, a bGS of 6 and a PSA 
of between 10-20  ng.ml, preoperative MRI was capable 
of predicting sPGU and BCR. Based on these results, we 
suggest that patients with FIR PCa who had a negative 
preoperative MRI and minimal tumor volume as assessed 
by biopsy are ideal candidates for AS.
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